Risk of Relapse Upon Treatment Discontinuation in Rosacea: An Updated Systematic Review and Network Meta‐Analysis of Randomized Controlled Trials
Authors:
- Ilaria TraveITIlaria Trave
- Francesco BellinatoFBFrancesco Bellinato
- Ilaria SalviISIlaria Salvi
- Andrea PrianoAPAndrea Priano
- Aurora ParodiAPAurora Parodi
- Paolo GisondiPGPaolo Gisondi
- Giampiero GirolomoniGGGiampiero Girolomoni
- Emanuele CozzaniECEmanuele Cozzani
Open Access
- 19 January 2026
- journal article
- review article
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Abstract
Background: Rosacea treatments often lead to recurrence after discontinuation, highlighting the need for effective maintenance therapies. The long‐term efficacy of treatments in preventing relapse has not been systematically compared. Objectives: To compare the risk of relapse upon treatment discontinuation after achieving clinical remission with both topical and systemic therapies. Methods: Updated systematic review and network meta‐analysis of randomized controlled studies following PRISMA guidelines. A thorough literature search across different databases to identify randomized controlled trials (RCTs) on treatment relapse rates in adult patients with moderate to severe papulopustular rosacea treated with systemic and topical treatments was conducted. Data were independently extracted, and the risk of bias was assessed using the Cochrane tool. Statistical analyses were performed using network meta‐analysis with random effects models. Results: A total of seven out of an initial 14,450 articles screened were retrieved, involving 632 patients with moderate to severe rosacea and 552 controls treated with metronidazole 0.75% gel, doxycycline 40 mg, ivermectin 1% cream, isotretinoin 0.25 mg/kg/day, hydroxychloroquine 200 mg, and aminolevulinic acid photodynamic therapy. Results showed that isotretinoin and metronidazole significantly prevented rosacea relapse compared to placebo, with isotretinoin ranked as the most effective treatment according to SUCRA rankings. The average time regarding relapse varied among studies, with metronidazole showing a shorter relapse period (12 weeks) than ivermectin (21 weeks). The risk of bias was low, with no significant publication bias detected. The limits of this review were the relatively small number of studies included and the high degree of indirectness that was noted across these studies, potentially affecting the reliability of some estimates. Conclusion: Rosacea remission can be maintained for a certain period of time after the discontinuation of the treatment and also during the treatments. Isotretinoin might be effective in reducing the risk of relapse.Keywords
This publication has 28 references indexed in Scilit:
- 5-Aminolevulinic acid photodynamic therapy versus minocycline for moderate-to-severe rosacea: A single-center, randomized, evaluator-blind controlled studyJournal of the American Academy of Dermatology, 2023
- Efficacy and safety of hydroxychloroquine for treatment of patients with rosacea: A multicenter, randomized, double-blind, double-dummy, pilot studyJournal of the American Academy of Dermatology, 2021
- Topical Ivermectin in the Treatment of Papulopustular Rosacea: A Systematic Review of Evidence and Clinical Guideline RecommendationsDermatology and Therapy, 2018
- RosaceaNew England Journal of Medicine, 2017
- A Randomized-Controlled Trial of Oral Low-Dose Isotretinoin for Difficult-To-Treat Papulopustular RosaceaJournal of Investigative Dermatology, 2016
- Assessment of rosacea severity: A review of evaluation methods used in clinical trialsJournal of the American Academy of Dermatology, 2015
- Checking consistency in mixed treatment comparison meta‐analysisStatistics in Medicine, 2010
- Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statementInternational Journal of Surgery, 2010
- Efficacy of Low-Dose Isotretinoin in Patients With Treatment-Resistant RosaceaArchives of Dermatology, 1998
- Topical Metronidazole Maintains Remissions of RosaceaArchives of Dermatology, 1998